Table 2.
68Ga-PSMA PET/CT: Summary of imaging results - status October 2017
| PRIMARY STAGING | SECONDARY STAGING | ||
|---|---|---|---|
| Sachpekidis et al. [39] n = 24 |
Increased tracer accumulation with time | Ceci et al. [50] n = 70 |
PSAdt 6.5 months & PSA 8.8 ng/ml are cut-off values for PET positivity |
| Uprimny et al. [40] n = 90 |
Detection rate is dependent on GS and PSA level | Verburg et al. [51] n = 155 |
PET positivity: PSA levels and shorter PSAdt are independent predictors |
| Maurer et al. [41] n = 130 Maurer et al. [67] n = 92 Maurer et al. [75] n = 332 |
Superior detection rate compared to CT/mpMRI in high- to intermediate-risk patients Superiority to conventional imaging proved by histopathology PET/CT < PET/MR |
Afshar-Oromieh et al. [54] n = 319 Afshar-Oromieh et al. [55] n = 1007 Afshar-Oromieh et al. [86], n = 112 |
Positivity correlates with PSA level and ADT but not with PSAdt and GS Increased detection by additional late imaging at 3 h p.i. |
| Eiber et al. [66] n = 53 |
Superiority of PET mpMRI over mpMRI or PET alone but no correlation with GS and PSA value | Eiber et al. [56] n = 248 Einspieler et al. [57] n = 118 |
Scan positivity correlates with GS but not with ADT Superiority to CT Detection rate correlates with PSA level and concomitant ADT |
| Giesel et al. [68] n = 10 Zamboglou [69, 70] n = 22 |
PET/CT and mpMRI correlate with tumor allocation proven by histopathology | Morigi et al. [85] n = 38 |
Superiority over 18F–cholin Management impact in 63% of patients |
| Budäus et al. [42] n = 30 |
LN detection rate is determined by LN size as proven by pathohistology | Pfister et al. [80] n = 28 |
Superior detection of local recurrence and/or metastases |
| van Leeuwen et al. [44] n = 30 |
LN detection rate is dependent on LN size | van Leeuwen et al. [53] n = 70 (PSA 0.05–0.1 ng/ml) | Management change in 28.6% of patients with impact on changes in RT-volume |
| Herlemann et al. [45] n = 20 |
Increased sensitivity of PSMA-PET to CT proven by histopathology | Herlemann et al. [45] n = 14 |
Increased sensitivity of PSMA-PET to CT |
| Demirkol et al. [46] n = 8 |
Increased sensitivity of PSMA-PET to CT | Kabasakal et al. [58] n = 50 |
PET positivity correlates with PSA level and GS |
| Sterzing et al. [47] n = 15 |
increased sensitivity of PSMA-PET to CT | Sachpekidis et al. [59] n = 31 |
Positivity correlates with PSA level; increasing uptake during dynamic PET acquisition |
| Sahlmann et al. [48] n = 12 |
Increased detection with late imaging under furosemide | Rauscher et al. [61] n = 48 |
Superior to conventional imaging proved by histopathology |
| Iagaru et al. [71] n = ongoing prospective study |
of PET/mpMRI in intermediate- and high-risk patients | Kranzbühler et al. [72] n = 56 |
Superiority of PET/mpMRI over PET/CT for local recurrence |
| Giesel et al. [38] n = ongoing prospective study | Ongoing prospective study of PET/CT in intermediate and high-risk patients | Freitag et al. [73, 74] n = 119 |
Superiority of PET/mpMRI over PET/CT for local recurrence but not for distant metastases |
| Schmuck et al. [87] n = 184 |
In 5.4% of patients increased detection rate with delayed imaging | ||
| Uprimny et al. [88] n = 80 |
In 9.4% increased detection rate by dynamic imaging | ||